Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Equal Weight

Wells Fargo analyst Derek Archila upgraded Celldex Therapeutics (NASDAQ: CLDX) from Underweight to Equal Weight with a price target of $27.00.

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $25.78 yesterday.

You May Also Be Interested In

• BofA Securities Upgrades Saia Inc. (SAIA) to Buy
• JPMorgan Upgrades Tokyo Century (8439:JP) to Overweight
• Macquarie Upgrades Kinsus Interconnect Technology Corp (3189:TT) to Outperform